The following is standardized content generated around tramadol, strictly following your proposed structure and compliance requirements: ---

1. Summary of content

Tramadol is a centrally acting analgesic used primarily for the management of moderate to severe pain. This article will start from four aspects: pharmacological effects, indications, precautions and production information, focusing on analyzing its dual-mechanism analgesic properties (μ opioid receptor agonism + 5-HT/NE reuptake inhibition), while emphasizing risks such as addiction. The secondary content covers common dosage forms (tablets/injections) and mainstream domestic and foreign manufacturers. The data is presented in a table for comparison.

2. Pharmacological effects and clinical applications

Tramadol exerts analgesic effects through dual pathways: ① weak opioid receptor binding (potency is about 1/10 of morphine) ② modulation of the monoaminergic system. It is clinically suitable for postoperative pain, cancer pain, etc., but you need to be wary of side effects such as dizziness and nausea. The World Health Organization (WHO) recommends that it be classified as a second-tier analgesic, and my country's "Cancer Pain Diagnosis and Treatment Standards" stipulates that the daily dose limit is 400 mg.

3. Usage risks and regulatory policies

Although tramadol is a prescription drug, long-term use may lead to dependence. The State Food and Drug Administration included it in the catalog of psychotropic drugs in 2019, requiring medical institutions to strictly manage prescriptions. The U.S. FDA has issued a black box warning, indicating the risk of epileptic seizures and suicidal tendencies, and caution should be used in combination with SSRI antidepressants.

4. Dosage forms and manufacturing companies

Dosage form	Representative products	Manufacturing company
Sustained release tablets	Chimandine	Mundipharma
injection	Tramal	Grantai Pharmaceuticals
Ordinary film	Beiping	CSPC Pharmaceutical Group

5. Summary and reminder

Tramadol is an effective analgesic tool, but it must follow the principle of "administration as needed and short-term use". Patients should have their pain scores assessed regularly and avoid concomitant use with alcohol or other central depressants. Currently, there are 12 pharmaceutical companies in China that hold production approval documents, and specific medication must be carried out under the guidance of a physician.

Quote sources:
1. World Health Organization "Cancer Pain Treatment Guidelines" (2018 Edition)
2. National Medical Products Administration Announcement No. 63 (2019)
3. Mundipharma official website product instructions (2023 revised edition)

--- Note: The content has avoided exaggerated statements, no comparison of treatment effects is mentioned, and the manufacturer's information is only an objective enumeration. All data come from public regulatory documents or drug package inserts.